Ton Slagboom1, MD; Ralph Toelg2, MD; Bernhard Witzenbichler3, MD; Michael Haude4, MD; Monica Masotti5, MD; Rafael Ruiz Salmeron6, MD; Adam Ryszard Witkowski7, MD; Masaaki Uematus8, MD; Akihiko Takahashi9, MD; Ron Waksman10, MD; Shigeru Saito11, MD
1. Cardiology Unit, OLVG, Amsterdam, the Netherlands; 2. Herzzentrum, Segeberger Kliniken, Bad Segeberg, Germany; 3. Department of Cardiology and Pneumology, Helios Amper-Klinikum, Dachau, Germany; 4. Lukaskrankenhaus Medizinische Klinik I, Städtische Kliniken Neuss, Neuss, Germany; 5. Department of Cardiology, Hospital Clínic de Barcelona, Barcelona, Spain; 6. Haemodynamic Unit, Hospital Universitario Virgen Macarena, Seville, Spain; 7. National Institute of Cardiology, Warsaw, Poland; 8. Kansai Rosai Hospital Cardiovascular Center, Amagasaki, Japan; 9. Sakurakai Takahashi Hospital, Kobe, Japan; 10. MedStar Health Research Institute, Washington, DC, USA; 11. Okinawa Tokushukai Shonan Kamakura General Hospital, Kamakura, Japan
Figures 1A and 1C of this article have been replaced in the online version. DP-SES has been replaced with DP-EES. 17th January 2022.
A large body of evidence is available for biodegradable polymer stents1, but long-term data are scarce and predominantly evaluated for Caucasian subjects. The BIOFLOW-IV trial aimed to provide additional data, comparing the safety and effectiveness of the ultrathin Orsiro biodegradable polymer sirolimus-eluting stent (BP-SES; Biotronik) with the XIENCE Prime/XIENCE Xpedition durable polymer everolimus-eluting stent (DP-EES; Abbott). We herein report final 5-year data.
The BIOFLOW-IV study has been described previously2, and is registered at ...
No account yet? Create my pcr account
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases
clinical trialsdrug-eluting stentmiscellaneous
Read next article
A bench study of balloon-expandable valves for the treatment of self-expanding valve failure